Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.

Literature DB >> 15273142

In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.

David J Farrell¹, Ian Morrissey, Sarah Bakker, Sylvie Buckridge, David Felmingham.

Abstract

To date, 86 of 7,746 macrolide-resistant Streptococcus pneumoniae isolates from 1999 to 2002 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) surveillance studies were negative for methylase and efflux mechanisms. Mutations in 23S rRNA or the genes encoding riboprotein L4 or L22 were found in 77 of 86 isolates. Six isolates were resistant to quinupristin-dalfopristin and two were resistant to linezolid, while telithromycin demonstrated good activities against all isolates.

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15273142 PMCID： PMC478535 DOI： 10.1128/AAC.48.8.3169-3171.2004

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

10 in total

1. Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.

Authors: F Depardieu; P Courvalin
Journal: Antimicrob Agents Chemother Date: 2001-01 Impact factor: 5.191

2. Emergence of macrolide resistance during treatment of pneumococcal pneumonia.

Authors: Daniel M Musher; Mark E Dowell; Virginia D Shortridge; Robert K Flamm; James H Jorgensen; Pierre Le Magueres; Kurt L Krause
Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245

3. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.

Authors: Ronald N Jones; David J Farrell; Ian Morrissey
Journal: Antimicrob Agents Chemother Date: 2003-08 Impact factor: 5.191

4. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors: Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191

5. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors: A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

6. Ribosomal mutations in Streptococcus pneumoniae clinical isolates.

Authors: Marja Pihlajamäki; Janne Kataja; Helena Seppälä; John Elliot; Maija Leinonen; Pentti Huovinen; Jari Jalava
Journal: Antimicrob Agents Chemother Date: 2002-03 Impact factor: 5.191

7. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Authors: A Tait-Kamradt; T Davies; P C Appelbaum; F Depardieu; P Courvalin; J Petitpas; L Wondrack; A Walker; M R Jacobs; J Sutcliffe
Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191

8. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization.

Authors: D J Farrell; I Morrissey; S Bakker; D Felmingham
Journal: J Antimicrob Chemother Date: 2001-10 Impact factor: 5.790

9. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study.

Authors: D J Farrell; I Morrissey; S Bakker; D Felmingham
Journal: J Antimicrob Chemother Date: 2002-09 Impact factor: 5.790

10. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.

Authors: D J Farrell; S Douthwaite; I Morrissey; S Bakker; J Poehlsgaard; L Jakobsen; D Felmingham
Journal: Antimicrob Agents Chemother Date: 2003-06 Impact factor: 5.191

10 in total

30 in total

Review 1. Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors: Katherine S Long; Birte Vester
Journal: Antimicrob Agents Chemother Date: 2011-12-05 Impact factor: 5.191

2. In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors: G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal: Hippokratia Date: 2015 Jan-Mar Impact factor: 0.471

3. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.

Authors: Steven D Brown; David J Farrell; Ian Morrissey
Journal: J Clin Microbiol Date: 2004-11 Impact factor: 5.948

4. Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.

Authors: M Rantala; S Huikko; P Huovinen; J Jalava
Journal: Antimicrob Agents Chemother Date: 2005-10 Impact factor: 5.191

5. Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.

Authors: Todd A Davies; Karen Bush; Daniel Sahm; Alan Evangelista
Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191

6. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus.

Authors: Nicole Wolter; Anthony M Smith; David J Farrell; William Schaffner; Matthew Moore; Cynthia G Whitney; James H Jorgensen; Keith P Klugman
Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191